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Developmental regulation of expression of
schizophrenia susceptibility genes in the primate
hippocampal formation
G Favre1, P Banta Lavenex1,2 and P Lavenex1,2
The hippocampal formation is essential for normal memory function and is implicated in many neurodevelopmental,
neurodegenerative and neuropsychiatric disorders. In particular, abnormalities in hippocampal structure and function have been
identified in schizophrenic subjects. Schizophrenia has a strong polygenic component, but the role of numerous susceptibility
genes in normal brain development and function has yet to be investigated. Here we described the expression of schizophrenia
susceptibility genes in distinct regions of the monkey hippocampal formation during early postnatal development. We found
that, as compared with other genes, schizophrenia susceptibility genes exhibit a differential regulation of expression in the
dentate gyrus, CA3 and CA1, over the course of postnatal development. A number of these genes involved in synaptic
transmission and dendritic morphology exhibit a developmental decrease of expression in CA3. Abnormal CA3 synaptic
organization observed in schizophrenics might be related to some specific symptoms, such as loosening of association.
Interestingly, changes in gene expression in CA3 might occur at a time possibly corresponding to the late appearance of the first
clinical symptoms. We also found earlier changes in expression of schizophrenia susceptibility genes in CA1, which might be
linked to prodromal psychotic symptoms. A number of schizophrenia susceptibility genes including APOE, BDNF, MTHFR and
SLC6A4 are involved in other disorders, and thus likely contribute to nonspecific changes in hippocampal structure and function
that must be combined with the dysregulation of other genes in order to lead to schizophrenia pathogenesis.
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Introduction
The hippocampal formation is implicated in a number of
neurodevelopmental, neuropsychiatric and neurodegenera-
tive disorders including schizophrenia,1 autism spectrum
disorders,2 temporal lobe epilepsy,3 Down syndrome,4
Williams syndrome,5 antisocial personality disorder and
psychopathy,6 bipolar disorders,7 major depressive disorder8
and Alzheimer’s disease.9 Although these pathologies are all
associated with abnormalities in hippocampal structure or
function, they exhibit specific characteristics, such as indivi-
dual groups of susceptibility genes and the fact that distinct
regions of the hippocampal formation are differentially
affected in specific pathologies.10
The hypothesis that schizophrenia emerges from the
interaction between genetic predispositions and environmen-
tal factors is now widely accepted.11 The genetic component
of schizophrenia was first suspected since relatives of
subjects with schizophrenia are more likely to get the illness
themselves.12 Indeed, the risk of suffering from schizophrenia
in the general population is about 1%; people who have a
third-degree relative (great grandparent, first cousin) with
schizophrenia are twice as likely to develop schizophrenia
(2%); those with a second-degree relative (grandparent,
uncle, aunt) have an incidence varying from 2 to 6%; finally
first-degree relatives (parent, sibling) have an incidence of
schizophrenia410 times higher than the general population
(13% for children, 17% for twins and 48% for identical twins).13
Accordingly, linkage analysis, gene expression and genome-
wide association studies have identified a number of schizo-
phrenia susceptibility genes.14,15
The fact that schizophrenia more often appears in late
adolescence and early adulthood suggests that schizophrenia
is a disorder of developmental origin. Moreover, prodromal
symptoms like affective disorders, substance abuse, person-
ality disorder, autism spectrum disorder-like symptoms,
developmental delays, delusions or hallucinations can be
found in patients years before they finally develop schizo-
phrenia.16 This suggests that the dysregulation of expression
of schizophrenia susceptibility genes might affect normal
brain development, leading to the gradual appearance of
different symptoms at different ages.
Magnetic resonance imaging studies consistently report
reduced hippocampal volumes in first-episode schizophrenic
subjects17 and asymptomatic, first-degree relatives of subjects
with schizophrenia,18 indicating that hippocampal pathology is
not the result of the illness or treatment but rather contributes to
the etiology of the disorder. The absence of obvious signs of
neurodegeneration confirms the idea that schizophrenia is a
neurodevelopmental disorder,19 which might arise following
the abnormal maturation of specific hippocampal circuits.20,21
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Here we analyzed the expression of 173 schizophrenia
susceptibility genes in distinct regions of the monkey
hippocampal formation during early postnatal development,
in order to assess the contribution of these genes to the normal
development of the hippocampal formation and shed light on
the pathogenesis of schizophrenia. We further considered
schizophrenia susceptibility genes involved in other diseases,
including temporal lobe epilepsy, autism spectrum disorder,
Williams syndrome, psychopathy, major depressive disorder,
bipolar disorder and Alzheimer’s disease, in order to better
comprehend the possible relations between gene dysregula-
tion, neuropathology and clinical symptoms.
Materials and methods
RNA samples. Sixteen male rhesus monkeys (Macaca
mulatta; four 1-day-old, four 6-month-old, four 1-year-old
and four 6–12-year-old) were used for this study. These
animals were the same used in previous studies.22,23 We
refer the reader to these publications for detailed descriptions
of RNA sample acquisition and microarray analyses using
the GeneChip Human Genome U133 Plus 2.0 (Affymetrix,
Santa Clara, CA, USA).
Data analysis. Analyses of gene expression levels were
performed with Genespring GX 11 (Agilent Technologies,
Santa Clara, CA, USA) and a custom-made script for
repeated-measures analysis of variance. Probe-level analysis
was performed with the Robust Multichip Averaging algorithm.
Data were log2 transformed and an analysis of variance was
performed in order to identify genes with differential expres-
sion in distinct hippocampal regions at different ages.
Adjusted P-values for multiple comparisons were calculated
with the false discovery rate method of Benjamini and
Hochberg.24 We found 15 392 probesets exhibiting signifi-
cantly different expression between ages (corrected P-values
o0.05); 33 147 probesets exhibiting significantly different
expression between regions (corrected P-valueso0.05); and
9511 probesets exhibiting a differential expression between
ages and regions (interaction age  region; corrected P-
valueso0.05). Only genes represented in one of these three
groups of probesets were considered for the follow-up
analyses (17 002 genes). We performed statistical analyses
comparing gene expression between newborns and adults
within distinct hippocampal regions (that is, entorhinal cortex,
dentate gyrus, CA3, CA1, subiculum) using two-tailed
unpaired t-tests (significance level was set at Po0.05).
Gene expression patterns. The specific genes exhibiting
either a significant increase or decrease in expression in any
of the five hippocampal regions, among the 173 schizo-
phrenia susceptibility genes15 and among all human protein-
coding genes (20 741) present in our microarray data, are
listed in Supplementary Information 1 and 2. When one gene
was represented by more than one probeset, we only
considered the probeset exhibiting the largest change. As
described in a previous study,23 some genes may be
represented by different probesets exhibiting opposite
patterns of expression; with an upregulated pattern that
might represent the expression of microRNA targeting that
gene, rather than mRNA. We therefore eliminated the
probeset susceptible to represent microRNA expression.
Finally, for genes that were identified as particularly
important for the functional analyses, we examined the
characteristics and specificity of the probesets, and non-
specific probesets were eliminated. Supplementary
Information 3 presents the gene expression patterns of the
probesets representing the 173 schizophrenia susceptibility
genes considered here.
Functional analyses. We used the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID) func-
tional annotation tool25 to perform functional analyses of
particular gene groups. DAVID provides the number of genes
for each enriched functional term in a given list of genes, the
percentage of total genes involved, and calculates a modified
Fisher’s exact P-value comparing the number of genes
included in a functional category and the number of genes
present in a control list (genes randomly chosen in the
Affymetrix H133 Plus 2.0 by DAVID, Affymetrix, Santa Clara,
CA, USA).
Results
Gene expression patterns
Schizophrenia. We found that a greater proportion of schizo-
phrenia susceptibility genes, as compared with all human
protein-coding genes, exhibited a downregulation of their
expression from birth to adulthood in distinct hippocampal
regions: dentate gyrus (ratio schizophrenia genes/all genes:
1.82; chi-square(1): 13.361, Po0.001), CA3 (ratio: 1.40; chi-
square(1): 7.783, Po0.01) and CA1 (ratio: 1.47; chi-
square(1): 13.406, Po0.001; Figure 1 and Supplementary
Information 2). In contrast, a smaller proportion of schizo-
phrenia susceptibility genes, as compared with all genes,
exhibited an upregulation of their expression from birth to
adulthood in CA3 (ratio: 0.63; chi-square(1): 4.138, Po0.05)
and CA1 (ratio: 0.42; chi-square(1): 9.150, Po0.005). These
findings suggest that schizophrenia susceptibility genes are
particularly involved in the postnatal development of the
hippocampal formation, and point to the dentate gyrus, CA3
and CA1, as crucial regions in the pathogenesis of schizo-
phrenia. Consequently, we analyzed in more detail the
expression patterns of these genes in these three regions.
Dentate gyrus. Among the 33 schizophrenia susceptibility
genes that exhibited lower expression levels in adult than
newborn monkeys, 13 (39%) exhibited a higher expression
level at birth than at any other age, 8 (24%) exhibited a lower
expression in adulthood than at any other age, and 4 (12%)
exhibited a higher expression in newborn and 6-month-old
monkeys, as compared with 1-year-old and adult monkeys
(Figure 2a, Supplementary Information 1 and 3).
CA3. Among the 54 schizophrenia susceptibility genes that
exhibited lower expression levels in adult than newborn
monkeys, 34 (63%) exhibited a lower expression level in
adults as compared with any other age (Figure 2b,
Supplementary Information 1 and 3).
CA1. Among the 67 schizophrenia susceptibility genes that
exhibited lower expression levels in adult than newborn
monkeys, 35 (52%) genes exhibited a higher expression level
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in newborn monkeys as compared with any other age
(Figure 2c, Supplementary Information 1 and 3).
In sum, the gene expression patterns observed in CA3 and
CA1 suggest that schizophrenia susceptibility genes might
impact the normal maturation of these two distinct hippocam-
pal regions at different postnatal stages.
Multiple pathologies. We further considered schizophrenia
susceptibility genes implicated in other disorders in order to
comprehend the possible relations between gene dysregula-
tion, neuropathology and clinical symptoms. In all, 28 of the
173 schizophrenia susceptibility genes (16%) are also
implicated in other neuropsychiatric disorders that exhibit
neuroanatomical or functional abnormalities in the hippo-
campal formation (Table 1). Among these genes, 10 are
implicated in temporal lobe epilepsy,26,27 8 in psychopathy-
antisocial personality disorder,28–30 7 in autism spectrum
disorder,31–34 7 in major depressive disorder,35–38 6 in bipolar
disorder,39–44 2 in Alzheimer’s disease45,46 and 1 in Williams
syndrome.47 There was no overlap between groups of genes
implicated in schizophrenia and Down syndrome.48 As
compared with all genes exhibiting a change in expression
from birth to adulthood, we found a greater proportion of
multiple pathology susceptibility genes exhibiting a down-
regulation of their expression from birth to adulthood in the
dentate gyrus (ratio: 3.06; chi-square(1): 13.913, Po0.001),
CA3 (ratio: 1.76; chi-square(1): 4.629, Po0.05) and CA1
(ratio: 1.62; chi-square(1): 3.899, Po0.05; Figure 3 and
Supplementary Information 4). We did not find differences
among genes exhibiting an upregulation of their expression
from birth to adulthood in any region.
Functional analyses
Schizophrenia. In order to characterize the cellular pro-
cesses that might be affected in schizophrenia, we sought to
determine the specific genes and functional processes
regulated in the dentate gyrus, CA3 and CA1 (Table 2). In
the dentate gyrus, schizophrenia susceptibility genes that
were regulated during postnatal development were linked to
neurogenesis, neuron and glial differentiation, axogenesis as
well as to cell adhesion molecules. In CA3, schizophrenia
susceptibility genes that were regulated were linked to
dendritic morphology, synaptic plasticity, synaptic transmis-
sion and neuron projection. These findings are consistent
with changes in neurotransmitter markers and synaptic
morphology in CA3 in schizophrenia.49,50 One functional
group comprises the GluN2B glutamatergic receptor subunit,
which might be linked to ‘associative learning’ impairments
observed in schizophrenics. The functional group ‘calcium
pathway’ was only identified in CA1. ‘Startle response’, which
Figure 2 Expression patterns of schizophrenia susceptibility genes regulated in the dentate gyrus, CA3 and CA1 from birth to adulthood. (a) Dentate gyrus. (b) CA3: 34
schizophrenia susceptibility genes (63%, solid lines) exhibit a significantly lower expression in adults than at any other ages. (c) CA1: 35 schizophrenia susceptibility genes
(52%, solid lines) are significantly more expressed at birth than at any other ages. Error bars represent s.e.
Figure 1 Percentages of schizophrenia susceptibility genes regulated in distinct hippocampal regions from birth to adulthood. (a) Decreased expression. (b) Increased
expression. Schizophrenia susceptibility genes (173; dark gray); protein-coding human genes (20 741; light gray). DG, dentate gyrus; EC, entorhinal cortex; Sub, subiculum.
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is identified as a functional group in the dentate gyrus and
CA1, is not related directly to any known schizophrenic
symptoms, but it is associated with the impairment in
prepulse inhibition observed in schizophrenics. The most
important functional process identified in the schizophrenia
susceptibility genes upregulated in both CA3 and CA1 is
related to ‘inflammatory response’, which might produce an
imbalance in N-methyl-D-aspartate (NMDA)-mediated gluta-
matergic neurotransmission.
Multiple pathologies. The involvement of genes in different
pathologies suggests that they contribute to alterations of
nonspecific processes implicated in all these disorders. Here
we consider the function and the expression patterns of four
of these genes in order to characterize the fundamental
processes that might link them to these disorders.
APOE. The role of APOE in the regulation of glutamatergic
neurotransmission might explain its implication in schizo-
phrenia,51 major depressive disorder in the elderly,52,53
Table 1 Twenty-eight schizophrenia susceptibility genes are also implicated in other neuropsychiatric disorders that exhibit neuroanatomical or functional
abnormalities in the hippocampal formation
Genes
Diseases
Significant differences in expression between newborn and adult monkeys
Adult4newborn Newborn4adult
SCZ EPI ASD DEP PSY BP ALZ WIL EC DG CA3 CA1 Sub EC DG CA3 CA1 Sub
SLC6A4 x x x x x
BDNF x x x x x x
APOE x x x x x x x
SLC6A3 x x x x
MTHFR x x x
DISC1 x x x
CHRNB2 x x x x x
HTR2A x x x
MAOA x x x x x
DRD2 x x x x
SLC1A2 x x x x x x x
COMT x x x x x x
AR x x x
GABBR1 x x x x
GABRG2 x x x x x x
IL10 x x
IL1B x x x x
TNF x x
AHI1 x x x x
DRD5 x x x x
FOXP2 x x x
PTPRZ1 x x x x x x
RELN x x x
GRM3 x x x x
DAO x x x
GRIN2B x x x x x
STX1A x x x x
SLC18A1 x x x
Total number 28 10 7 7 8 6 2 1 2 4 2 2 1 2 9 11 12 4
Percentage 36% 25% 25% 29% 21% 7% 4% 7% 14% 7% 7% 4% 7% 32% 39% 43% 14%
Abbreviations: ALZ, Alzheimer’s disease; ASD, autism spectrum disorder; BP, bipolar disorder; DEP, major depressive disorder; DG, dentate gyrus; EC, entorhinal
cortex; EPI, temporal lobe epilepsy; PSY, psychopathy antisocial personality disorder; SCZ, schizophrenia; Sub, subiculum; WIL, Williams syndrome.
Figure 3 Percentages of schizophrenia susceptibility genes also involved in other diseases, which are regulated in distinct hippocampal regions from birth to adulthood.
(a) Decreased expression. (b) Increased expression. Schizophrenia susceptibility genes also involved in other diseases (28; dark gray); protein-coding human genes (20 741;
light gray). DG, dentate gyrus; EC, entorhinal cortex; Sub, subiculum.
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temporal lobe epilepsy26 and Alzheimer’s disease.54 Indeed,
one of the main physiological processes influenced by
different alleles of APOE is the sequestration of NMDA and
AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolpropio-
nate) receptors in intracellular compartments, which could,
in turn, lead to changes in long term potentiation (LTP)
induction and neuronal degeneration.55
MTHFR. A mutation of the gene MTHFR, which
encodes the enzyme methylene-tetrahydrofolate reductase
involved in the homocysteine metabolic pathway, might
indirectly impact glutamatergic transmission, increasing non-
specifically the risk for different disorders. Indeed, MTHFR
contributes to the regulation of RELN,56 whose expression is
decreased in the hippocampus of subjects suffering from
Table 2 Functional analyses of schizophrenia susceptibility genes exhibiting differences in expression between newborn and adult monkeys in any one of five distinct
hippocampal regions
Adult4 newborn
EC DG CA3 CA1 Sub
Cell–cell signaling Axogenesis Cell–cell signaling Cell–cell signaling Apoptosis
Synaptic transmission Neuron differentiation Inflammatory
response
Inflammatory response Cell cycle
Transmission of nerve
impulse
Regulation of neurotransmit-
ter levels
Neurotransmitter
transport
Cell–cell signaling
Synaptic transmission Response to drug Positive regulation of
transport
Transmission of nerve
impulse
Response to drug
Vesicle-mediated transport Response to endogen-
ous stimulus
Tyrosine kinase signal-
ing pathway
Newborn4 adult
Cell adhesion Axogenesis Apoptosis Calcium signaling pathway Cell adhesion
Glutamate
neurotransmission
Cell adhesion Associative learning Cell cycle Cell differentiation
Inflammatory response Cell migration Dendrite
morphogenesis
Cyclic nucleotide Cell migration
monoamine
Neurotransmission Cyclic nucleotide G-protein signaling Dendrite morphogenesis Glial cell differentiation
Regulation of mem-
brane potential
G-protein signaling Glutamate
neurotransmission
G-protein signaling Neurogenesis response
to synaptic transmission
Endogenous stimulus Glial cell differentiation Inflammatory
response
GABA signaling pathway Transmission of nerve
impulse
Response to external
stimulus
Gliogenesis Monoamine
neurotransmission
Glial cell differentiation
Response to organic
nitrogen
Glutamate
neurotransmission
Neurogenesis Glutamate
neurotransmission
Synaptic transmission Lipid catabolic process Neuron
differentiation
Monoamine
neurotransmission
Transmission of nerve
impulse
Monoamine
neurotransmission
Neuron projection Neurogenesis
Multicellular organismal
response to stress
Nitrogen compound
metabolic process
Neuron differentiation
Neurogenesis Notch pathway Neuron projection
Neuron differentiation Regulation of mem-
brane potential
Nitrogen compound metabolic
process
Nitrogen compound meta-
bolic process
Synaptic plasticity Peptidyl-tyrosine modification
Phosphoinositide-mediated
signaling
Synaptic transmission Regulation of membrane
potential
Regulation of membrane
potential
Transmission of nerve
impulse
Regulation of transcription
Response to nutrient levels Tyrosine kinase sig-
naling pathway
Response to drug
Startle response Response to organic nitrogen
Synaptic plasticity Startle response
Synaptic transmission Synaptic plasticity
Transmission of nerve
impulse
Synaptic transmission
Transmission of nerve impulse
Tyrosine kinase signaling
pathway
DG, dentate gyrus; EC, entorhinal cortex; Sub, subiculum.
Groups in bold are highlighted in the Results and Discussion sections.
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schizophrenia and major depressive disorder.57 RELN
binds to the receptor APOER2 (which is also a receptor for
APOE), and might thus similarly modulate glutamatergic
neurotransmission.
BDNF. Dysregulation of BDNF, the gene coding for the
ubiquitous brain-derived neurotrophic factor, might also lead to
alterations of glutamatergic neurotransmission, as recently
shown in the human hippocampus.58 BDNF enhances
glutamate release, the frequency of miniature Excitatory
Postsynaptic Currents (mEPSCs), NMDA receptor activity
and the phosphorylation of NMDA receptor subunits.59 BDNF
expression is regulated by synaptic activity; it does not appear
to mediate changes in synaptic efficacy, but instead con-
tributes to the modulation of the capability of glutamatergic
synapses to undergo LTP and long term depression (LTD).60
SLC6A4. SLC6A4 codes for the high-affinity serotonin
transporter localized presynaptically, which has been impli-
cated in schizophrenia,61 temporal lobe epilepsy,62 autism
spectrum disorder, major depressive disorder36,63 and anti-
social personality disorder. This suggests that a dysregulation
of serotonin levels is common to different neuropsychiatric
disorders.
Discussion
We found that schizophrenia susceptibility genes are sig-
nificantly more regulated than other genes in the dentate
gyrus, CA3 and CA1 from birth to adulthood. These findings
are consistent with the hypothesis that hippocampal subfield
dysfunctions could underlie psychotic manifestations in
schizophrenia.20,21 We discuss the possible relations
between gene dysregulation, abnormal hippocampal devel-
opment, neuropathological findings and clinical symptoms
observed in schizophrenics.
Glutamatergic neurotransmission. Glutamatergic path-
ways are most prominently, although not exclusively,
affected in schizophrenia,19 and alterations of glutamatergic
neurotransmission in the hippocampal formation is thought to
be associated with some psychotic symptoms observed in
schizophrenia.20,21 In healthy subjects, ketamine, an NMDA
receptor antagonist, produces psychotic symptoms including
hallucinations and thought disorders, depersonalization and
derealization, as well as negative symptoms like apathy.64
Ketamine decreases cerebral blood flow in the hippocampus
of both control subjects and schizophrenics, reflecting a
deactivation of excitatory glutamatergic synapses; this effect
is greater in schizophrenics than in controls.65 Dysfunction of
glutamate neurotransmission might also be linked to hippo-
campus-dependent long-term memory impairments
observed in schizophrenics.66–69 Interestingly, inhibition of
glutamate neurotransmission by ketamine infusion in control
subjects disrupts verbal recognition memory and decreases
word event-related potentials in the anterior medial temporal
lobe.67
Accordingly, schizophrenia susceptibility genes regulated
in the dentate gyrus, CA3 and CA1 from birth to adulthood
belong to functional groups including neurotransmission, and
involve more specifically the glutamatergic system.
Decreases in AMPA, NMDA and kainate receptor subunits
expression have been shown in the dentate gyrus and
CA3 of schizophrenics.49 In contrast, an increase of GRIN2B
mRNA expression was reported in several hippocampal
regions.21
An important group of schizophrenia susceptibility genes
regulated in both CA3 and CA1 is related to ‘inflammatory
response’. Prenatal infection has been proposed to facilitate
the early sensitization of the immune system, which might
lead to an increased risk for schizophrenia.70 Mechanistically,
immune system dysfunction might lead to an increase of
kynurenine observed in schizophrenic patients.70 Kynurenine,
is a metabolite of tryptophan and is the only known
endogenous NMDA receptor antagonist. Inhibition of gluta-
matergic transmission in the hippocampus might lead to
psychotic symptoms like depersonalization, derealization,
hallucinations, thought disorders and apathy.64,70
Altogether, these findings suggest that an overall decreased
neurotransmission in the main excitatory pathways, as well as
a modulation of glutamatergic receptors activity, might lead to
the dysfunction of glutamatergic circuits within the hippocampal
formation.20 We discuss specific findings in the dentate gyrus,
CA3 and CA1, in turn.
The dentate gyrus. Abnormal expression of schizophrenia
susceptibility genes involved in neurogenesis could be linked
to the reduced cell proliferation reported in the dentate gyrus
of schizophrenics.71 However, the absence of obvious
changes in the total number of neurons19 suggests that
pathogenic factors that induce dentate gyrus dysfunction,
and have a role in schizophrenia, are unlikely to impact the
initial phase of postnatal developmental neurogenesis and
neuronal addition in the granule cell layer (which might
correspond to at least the first four postnatal years in
humans).10 Schizophrenia pathology, however, might impact
more subtle aspects of neurogenesis and dentate gyrus
function at later ages,20 without resulting in obvious
morphological signs of neuropathology.19 Indeed, the inclu-
sion of the functional group axogenesis in the schizophrenia
susceptibility genes regulated in the dentate gyrus might be
associated with the observations that there are fewer
synaptic contacts formed by dentate mossy fiber terminals
in CA3 and that the branched spines of CA3 pyramidal
neurons are smaller in schizophrenics.50 In addition, reduced
dysbindin-1 (coded by the gene DTNBP1) expression in the
inner molecular layer of the dentate gyrus is also consistent
with alterations of intrinsic dentate gyrus pathways.19,72
Disruption of one of the basic functions assigned to the
dentate gyrus, pattern separation,73 has not been reported
specifically in schizophrenics. However, disruption of the
dentate gyrus projections to CA3 might impact other functions
supported by CA3 or CA1. Changes in CA3 mossy fiber
synapses in schizophrenics may reduce the functional
contribution of the dentate gyrus to hippocampus-dependent
memory processes, diminishing dentate gyrus-mediated
pattern separation and possibly contributing to or potentiating
the CA3-mediated process of pattern completion, leading to
the loosening of association. As proposed by others,20,21 the
relative shift toward pattern completion could advantage
inappropriate associations, generate false or illogical mem-
ories, and create a susceptibility to psychosis.
Schizophrenia genes and hippocampus development
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CA3. Schizophrenia susceptibility genes regulated in CA3
during postnatal development were included in the functional
groups: dendritic morphology, synaptic plasticity and trans-
mission, neuron projection. This is consistent with the
alterations in glutamatergic and GABAergic synapses
observed in CA3.49 Specifically, the expression of the
glutamate receptor subunits GluA1 (GRIA1), GluA2 (GRIA2),
GluN1 (GRIN1), GluK5 (GRIK5) and the vesicular glutamate
transporter VGLUT1 (SLC17A7) is lower in the CA3 of
schizophrenics, as compared with controls.49 In contrast,
there is a higher expression of GRIN2B mRNA (coding for
the GluN2B receptor subunit),21 a schizophrenia suscept-
ibility gene. A corresponding increase in GluN2B-containing
NMDA receptors in CA3 would be consistent with the
symptom of loosening of association observed in schizo-
phrenia. Indeed, NMDA receptors containing the GluN2B
subunit, exhibit longer opening time than other NMDA
receptors. GRIN2B is normally downregulated during post-
natal development, which might contribute to the emergence
of more selective memory function in adult normal indivi-
duals. In adult schizophrenics, increased expression of
GluN2B might contribute to the formation of less specific,
illogical associations of information.
Accordingly, another functional group of schizophrenia
susceptibility genes regulated in CA3 is ‘associative learning’.
CA3 is thought to be central for the process of pattern
completion.74 As discussed above, disturbance of pattern
completion might contribute to the loosening of association
observed in schizophrenics.75 The majority of schizophrenia
susceptibility genes exhibiting lower expression in adults than
in newborns in CA3, show a lower expression in adulthood
than at any other age. This suggests that CA3 dysfunction
might manifest at relatively late developmental stages. This is
in agreement with the fact that looseness of association is
associated primarily with the acute stage of schizophrenia,76
which first occurs in late adolescence or early adulthood.
In sum, CA3 pathology might be especially involved in one
of the cardinal characteristics of schizophrenia: the loosening
of association. The fact that a majority of schizophrenia
susceptibility genes exhibit a downregulation of expression
relatively late during postnatal development in CA3 is
consistent with a late onset and diagnosis of schizophrenia.
CA1. Schizophrenia susceptibility genes regulated in CA1
were included in the functional groups: neurotransmission,
dendrite morphology, synaptic plasticity and axogenesis.
However, these genes exhibited a downregulation of their
expression earlier in CA1, as compared with CA3, and might
thus be linked to the early appearance of delusions and other
prodromal symptoms. CA1 hyperactivation is thought to result
from a dysregulation in dopamine neuromodulation, function-
ally isolating CA1 from its direct sensory inputs from the
entorhinal cortex, and thus leading to a relative increase in the
importance of its inputs from CA3. As shown in in vitro slice
preparations in rats, dopamine inhibits CA1 pyramidal cells’
response to perforant pathway stimulation but not to CA3
Schaffer collateral stimulation.77 In vivo, this might reduce
CA1’s response to specific sensory information coming from
the entorhinal cortex and lead to a discordant CA1 compar-
ison of the direct sensory input (via projections from the
entorhinal cortex) and the predictions based on the contents
of long-term memory provided by CA3. CA1 dysregulation,
whose early onset is associated with prodromal symptoms,
might be exacerbated when disrupted CA3 function manifests
at later ages, leading to the progression into a more typical
symptomatology compatible with the typical diagnosis of
schizophrenia.
Accordingly, a high-resolution functional imaging study
recently revealed an increase in cerebral blood flow in CA1 of
schizophrenics.78 Although brain activation also changed in
other brain regions, symptom severity correlated with abnor-
mal activity only in CA1. In addition, CA1 hyperactivity signal
was predictive of the development of psychosis in a prodromal
group (comprises patients who met ultra-high-risk criteria for
psychosis) and correlated positively with delusions. This
suggests that CA1 hyperactivity might contribute to the
generation of delusions and other positive symptoms.78
Conclusion
We found that schizophrenia susceptibility genes are sig-
nificantly more regulated than other genes, and differentially
regulated, in the dentate gyrus, CA3 and CA1 from birth to
adulthood. These findings are consistent with the hypothesis
that the developmental dysregulation of schizophrenia sus-
ceptibility genes in distinct hippocampal subfields might be
related to the emergence of specific symptoms. A number of
schizophrenia susceptibility genes including APOE, BDNF,
MTHFR andSLC6A4 are involved in other disorders, and thus
likely contribute to nonspecific changes in hippocampal
structure and function that must be combined with the
dysregulation of other genes in order to lead to schizophrenia
pathogenesis.
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